Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Quote. Delayed Swiss Exchange - 01/22 11:30:30 am
85.93 CHF   +0.37%
01/22NOVARTIS AG : Barclays keeps a Sell rating
MD
01/21NOVARTIS AG : annual earnings release
01/21NOVARTIS AG : Goldman Sachs reiterates its Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis : Genentech Get Expanded FDA OK of Xolair for Nasal Polyps

12/01/2020 | 12:12pm EST

By Colin Kellaher

Novartis AG and Roche Holding AG's Genentech unit on Tuesday said the Food and Drug Administration approved the expanded use of Xolair for the add-on maintenance treatment of nasal polyps in adults with inadequate response to intranasal corticosteroids.

The companies said the approval makes Xolair the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E, a key driver of inflammation.

Nasal polyps, which can lead to nasal congestion and a loss of smell, frequently occur with other respiratory conditions, such as allergies and asthma.

Xolair was already approved in the U.S. to treat moderate to severe persistent allergic asthma and chronic idiopathic urticaria. Novartis and Genentech work together to develop and co-promote Xolair in the U.S.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

12-01-20 1211ET

Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS AG 0.37% 85.93 Delayed Quote.2.73%
ROCHE HOLDING AG 0.54% 318.45 Delayed Quote.3.06%
All news about NOVARTIS AG
01/22NOVARTIS AG : Barclays keeps a Sell rating
MD
01/21NOVARTIS AG : annual earnings release
01/21NOVARTIS AG : Goldman Sachs reiterates its Buy rating
MD
01/20NOVARTIS AG : Credit Suisse reiterates its Neutral rating
MD
01/20NOVARTIS AG : Jefferies keeps its Buy rating
MD
01/19NOVARTIS AG : JP Morgan reaffirms its Sell rating
MD
01/19Novartis, GSK Kick Off Exploration of African Genetic Diversity to Improve Tr..
MT
01/19Novartis, GlaxoSmithKline Launch Research on Genetic Diversity in Africa
MT
01/19GSK, Novartis Announce Collaboration To Support Scientific Research Into Gene..
RE
01/19NOVARTIS : GSK and Novartis announce collaboration to support scientific researc..
AQ
More news
Financials (USD)
Sales 2020 49 185 M - -
Net income 2020 8 364 M - -
Net Debt 2020 20 185 M - -
P/E ratio 2020 26,4x
Yield 2020 3,26%
Capitalization 221 B 221 B -
EV / Sales 2020 4,90x
EV / Sales 2021 4,49x
Nbr of Employees 110 000
Free-Float 86,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 109,54 $
Last Close Price 97,04 $
Spread / Highest target 53,4%
Spread / Average Target 12,9%
Spread / Lowest Target -7,00%
EPS Revisions
Managers and Directors
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG2.73%220 726
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159
ABBVIE INC.3.46%195 720